Viking Therapeutics faces dilution and rising obesity competition, but VK2735's pipeline progress could offer catalysts and support a rebound.

Study to Explore Oral Maintenance Dosing Regimens Following Initial Weight Loss with Subcutaneous VK2735 Monthly and Every-Other-Week Subcutaneous Regimens to also be Evaluated SAN DIEGO, Oct. 6, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of an exploratory oral maintenance dosing study of VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity.

Get 'em while they're still on sale. Catalysts are on the horizon.

Eli Lilly's new data show Foundayo's cardiovascular safety and metabolic benefits, while EloraTZP delivers greater weight loss and A1C reduction in a mid-stage study.

Viking Therapeutics raised $575 million in a supplementary public offering after positive trial results. Share dilution reduces EPS by about 7.2%, and the earnings yield per dollar invested is now 14.4% lower.

Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $30.51, moving 6.41% from the previous trading session.

Could this be what Novo needs to turn things around?

Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $32.74, signifying a +2.92% move from its prior day's close.

Viking Therapeutics' leading candidate recently performed well in a maintenance clinical trial. The medicine could eventually become a notable player in the weight-loss market.

Viking Therapeutics' recent clinical trial results for its leading weight loss candidate were excellent. But Eli Lilly, the leader in this area, has a robust pipeline of its own and has little to fear from its smaller rival.